# The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

> **NCT03928275** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Carman Giacomantonio**

## Conditions studied

- Cutaneous Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Interleukin-2
- **BIOLOGICAL:** Combination therapy Interleukin-2 and Bacillus Calmette Guerin

## Key facts

- **NCT ID:** NCT03928275
- **Lead sponsor:** Carman Giacomantonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn prematurely.
- **Last updated:** 2023-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03928275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03928275, "The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT03928275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*